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Abstract
Aim: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to
undergoing genomic testing within a research program.
Methods: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology)
study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were
offered MTP in order to identify cognate therapies. Twenty patients, selected by purposive sampling, were interviewed
around the time they gave consent to MTP. Interviews were audio recorded, transcribed and analysed using thematic
analysis. Themes identified in the transcripts were cross-validated via qualitative responses to the PiGeOn study survey
(n = 569; 63%).
Results: All interviewed participants gave consent to MTP without reservation. Three themes were identified
and further supported via the survey responses: (1) Obvious agreement to participate, primarily because of
desire for new treatments and altruism. (2) The black box – while participant knowledge of genomics was
generally poor, faith in their oncologists and the scientific process encouraged them to proceed with testing;
and (3) Survival is the priority – receiving treatment to prolong life was the priority for all participants, and
other issues such as identification of a germline variant were generally seen as ancillary.
Conclusion: Having advanced cancer seemed to abrogate any potential concerns about MTP. Participants
valued the research for varied reasons, but this was secondary to their priority to survive. While no negative
attitudes toward MTP emerged, limitations in understanding of genomics were evident.
Keywords: Cancer, Qualitative, Molecular tumor profiling, Genomic, Patient attitudes, Psychosocial,
Interviews, Motivation
Background
Molecular tumor profiling (MTP) is a form of gen-
omic testing which aims to link molecular targets in
tumors to cognate therapies. This allows identification
of personalized treatment for cancer, such as poten-
tially identifying new agents for treating a particular
cancer and/or increasing efficacy of therapy while re-
ducing unnecessary side-effects [1]. MTP has entered
clinical practice, driven by improved technology,
patient demand and the need for more effective can-
cer treatments [2]. However, it is not known how pa-
tients will respond to the potential challenges of such
testing. A recent systematic review [3] found that
most of the scant research in this area has been
hypothetical. The little that is known suggests that
patients, despite misunderstandings about genomics,
are aware of the benefits of tumor testing (i.e.
informing treatment) and are willing to undergo test-
ing [4, 5]. However, patients have also reported some
concerns, including worries about psychological harm
related to intrusive thoughts due to unwanted know-
ledge. Potential privacy and insurance and/or employ-
ment discrimination are also of concern, though
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participant confusion with germline findings has also
been noted [4, 6].
MTP involves testing tumor samples for identifica-
tion of any genomic or molecular alterations to
guide treatment choices. These alterations can affect
treatment (clinically actionable), not affect treatment
(non-actionable) or be of uncertain significance.
There is a chance that germline variants, which
have implications for biological relatives, may be
identified [7]. In this case confirmatory testing is
warranted. Miller and colleagues found that in a
sample of patients with advanced cancer undergoing
MTP, feelings of family obligation were associated
with their willingness to receive such results, but
also that this information was perceived as burden-
some and/or inconsequential by patients, given their
disease stage [8].
There is concern that MTP may hold psychological
risks [9, 10]. It is possible that patients with a cancer
diagnosis may hold high hopes for MTP to provide
new treatments [11], and feel disappointed if no ac-
tionable result is found, even if they had been advised
that the chances of a useful outcome were low.
Equally, if clinically actionable results are found, and
the relevant drug is not available to the patient, or
they are deemed too unwell for treatment, they may
feel angry and abandoned.
This study aimed to elicit the attitudes and expecta-
tions of participants with advanced cancer towards MTP
and return of results prior to undergoing testing, to de-
termine what support and information may need to be
provided for patients in the clinical setting, specifically
at the time of consent.
Methods
Participants
The Molecular Screening and Therapeutics (MoST) Pro-
gram is a study underway at the Garvan Institute of Med-
ical Research in Sydney, Australia [12]. It is recruiting 1,
000 adult participants with pathologically confirmed
advanced or metastatic solid cancer, with a particular
focus on rare cancer. Participants undergo MTP and, if
there are actionable findings, are enrolled in a related
therapeutic trial if available (including access to immune
checkpoint inhibitors). The Psychosocial Issues in Gen-
omics in Oncology (PiGeOn) Project is a longitudinal,
mixed methods psychosocial sub-study of MoST, which
aims to examine the psychosocial, behavioral and ethical
impact of MTP [11, 13]. Participants gave written consent
to participate in PiGeOn while giving consent to partici-
pate in MoST. This sub-study was approved by the St
Vincent’s Hospital Human Research Ethics Committee.
Details of inclusion and exclusion criteria for MoST
are reported in full in the MoST protocol paper [12]. In
summary, the target population comprises adult partici-
pants with pathologically confirmed advanced or meta-
static solid cancers of any histological type, either during
or after their last line of effective therapy; participants
have Eastern Cooperative Oncology Group (ECOG) Per-
formance Status 0, 1 or 2; and have sufficient accessible
tissue for molecular profiling. Additional exclusion cri-
teria for the PiGeOn study were inability to comply with
study requirements, including timing and/or nature of
assessments; and inability to provide written informed
consent [13].
Data collection
Purposive sampling was used to ensure heterogeneity
(age, gender, cancer type) in the cohort. Eligible partici-
pants were invited to participate in a semi-structured
interview immediately after giving written consent for
MTP within the MoST Program, and to the PiGeOn
study. Consenting participants were interviewed by tele-
phone within 1–2 weeks, at a time of their choosing.
Semi-structured interviews were conducted by one
researcher (NB) and continued until data saturation
was reached (i.e. no new information after three con-
secutive interviews) [14]. Participants were asked
about their understanding of MTP, what influenced
their decision to participate, their attitudes toward
testing and return of results, managing uncertainty,
and who they thought should be able to access test-
ing (see Additional file 1). The interview questions
and follow-up prompts were developed iteratively as
required to develop themes identified during the
study analysis. Demographic details were collected
within the parent study (MoST).
In addition to the interview portion of the PiGeOn
study, a survey was administered to the entire cohort
(n = 898), which included an opportunity to provide
free-text responses to the questions: ‘What are the
benefits of MTP?’ and ‘What are the drawbacks of
MTP?’ Answers were extracted from the surveys and
content-analyzed alongside the interview data.
Analysis
Interviews were audio-recorded, transcribed verbatim,
and data was analyzed according to thematic analysis
[15]. Using line-by-line coding, multi-disciplinary re-
searchers (n = 8) developed initial codes from six tran-
scripts, which were synthesized into focused codes. This
initial thematic map was applied to additional tran-
scripts. Using the constant comparative method, new
codes were iteratively generated and applied to the data
set. Data collection and analysis occurred concurrently
as themes were refined and applied to the findings. Any
differences among researchers’ interpretations were re-
solved through discussion and negotiated consensus.
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The varied academic backgrounds of the researchers
(genetics, medicine, bioethics, psychology) ensured re-
flexivity [16].
The free-text responses from the survey were tabu-
lated and assessed using content analysis [17], allowing
for triangulation of data. Rigor was also derived from it-
erative discussions and review of the coding process by
the researchers until thematic coding was complete.
Results
Thematic saturation was reached when 20 participants
were interviewed. No-one who was approached refused
to be interviewed. Interviews were conducted between
August 2017 and June 2018 and averaged 26 min in
length. The mean age of the participants was 57.1 years,
and 45% were female. The average ECOG score at the
time of recruitment was 1 and the cancer diagnoses were
varied (Table 1).
Of the cohort that completed the survey (820/898 =
91%), 569 (63%) participants responded to the open-ended
question about perceived benefits and/or drawbacks of
MTP. This data from the free-text survey responses did
not reveal any themes beyond those captured in the inter-
views. Key themes derived from the open-ended written
responses are summarized in Table 2.
Three themes were identified, with sub-themes in
each category. The three main themes were (1): Obvi-
ous agreement to participate (2); The black box; and
(3) Survival is the priority.
1) Obvious agreement to participate
All participants reported no reservations to giving con-
sent to the MTP testing. In response to a question about
why they joined the MoST Program, the predominant
response was ‘Why wouldn’t you?’ All participants had
been undergoing tests and treatments for some time and
saw MTP as a continuation of the experience of having
advanced cancer. As one participant replied, ‘I didn’t
even give it that much thought, it was just another step
in the process I’m going through, because I’ll do anything
to try and find something that’s going to help me out. So,
yeah, I haven’t – didn’t really think too long or hard
about it; I just said, “yeah, I’ll do it.”’ (373, male, age 51–
60 years)
However, there were variations in the rationale given
for this immediate agreement to genomic testing, as
reflected in the four subthemes: a) Access to therapy; b)
Self-identified versus oncologist-identified; c) Altruism,
and D) Desperation.
a) Access to therapy
As participants were eligible for the MoST Program
only after they had exhausted all other treatment op-
tions, the majority were aware that this study was their
last chance to access further therapy. They felt that there
was nothing to lose and much to gain by participating.
‘Where death is looming every day, you know there’s ab-
solutely nothing to worry about here, it couldn’t get any
worse’. (Laughs) (356, male, age 51–60 years)
The MoST research program was seen as an oppor-
tunity to receive tailored therapy, thereby bypassing
the burdens of potentially avoidable side effects and
financial cost associated with non-targeted (and pos-
sibly ineffective) treatment. Further, the benefits for
joining the study were seen as broader than the
possibility of additional cancer therapy for many par-
ticipants. Undergoing MTP testing was viewed as a
way to contribute to the advancement of science and
medicine, with some suggesting that this was a moral
obligation for all people with cancer. While some
Table 1 Demographics
Qualitative sample n =
20
Quantitative sample (responders) n =
569
Quantitative sample (non-responders) n =
251
Average Age (years) 57.1 (range 41–77) 54 (range 18–85) 56 (range 19–88)
Female (%) 45 52 47
Average ECOG score at
recruitment
1 (range 0–2) 1 (range 0–2) 1 (range 0–2)
Cancer diagnosis (%)
Genito-urinary 30 17 15
Gastro-intestinal 25 22 24
Lung 10 4 3
Breast 5 5 8
Bone and soft tissue 10 21 21
CNS 5 6 12
Other 15 26 17
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participants perceived their participation in testing as
‘helping to find a cure for cancer’, others held more
modest expectations in hoping that if the study re-
sults did not help them, it might help someone else.
These benefits were seen to clearly outweigh any
drawbacks for MTP. MTP was viewed as a low-risk
and positive alternative to other avenues of finding
treatment such as online personal genomic testing
and surgical biopsy, as it was both free of charge and
non-invasive for participants. There was an underlying
trust in the treating oncologists who drew their atten-
tion to the study, which seemed to increase MTP’s
acceptability. ‘What have I got to lose? There was
really nothing to weigh up. You know, if I can help
somebody else then great, if I can help myself, even
better but, um, you know, it’s only time there’s nothing
very invasive - some blood and a bit of time’. (356,
male, age 51–60 years)
b) Self-identified versus oncologist-identified
Two pathways for identification of the study were
evident. Some participants had learnt about the MoST
Program online. Many had heard about dramatic
responses to immune checkpoint inhibitors while pro-
actively searching for treatment options and clinical
trials. These “self-referred” participants were charac-
terised by a higher engagement with study processes
and their knowledge of available treatment options.
These participants also perceived themselves (or the
spouse who drove the engagement with the research
program) as caring more about their outcomes than
anyone else: “no-one else cares as much as me”. (265,
male, age 41–50 years).
Others found out about the study through their treat-
ing oncologists. This subgroup of participants tended to
be more passive and accepting of what information was
proffered and were much less interested in the research
protocol than the self-referred group. A significant trust
in the oncologist’s opinion accompanied this position,
‘well, for me it was I trusted the doctor. You don’t tell the
plumber how to do the plumbing, so you don’t tell the
doctor how to do the doctoring.’ (375, female, age 61–70
years)
c) Altruism
While not a primary motivation for participating in
genomic testing, altruism played a part in the consider-
ations of most participants. This altruism was focused on
the community in general, or more specifically on family
members. Participation was seen as worthwhile, whether
or not a good outcome was experienced by the partici-
pant, if it meant that someone may benefit from their ‘ter-
rible’ cancer experience. The results from the research
were also seen to be of benefit to younger generations,
either as providing advance knowledge of a possible germ-
line variant, or improved hope for cancer cure through
early diagnosis. ‘Because it’s not – it’s not all about me,
mate, it’s about everybody that has this cancer’. (705, male,
age 71–80 years) (see Theme 3 below).
d) Desperation
A subgroup of participants reported a feeling of ‘des-
peration’ about extending their lives, noting that they
were running out of treatment options, as if they were a
‘ticking time-bomb’ with death increasingly close. There
was a pressing need to know that every treatment option
had been pursued. These participants reported finding it
difficult to wait 10 weeks for the results and were willing
to pay anything to access more treatment options, even
if the chance of a positive outcome was low, since it was
considered that any chance was better than no chance.
This sense of desperation seemed to increase the anxiety
they experienced when waiting for results. Participants
Table 2 Benefits and drawbacks of molecular tumour profiling (n = 569) *
Benefits Frequency Drawbacks Frequency
Access to personalised therapy 328 (42%) No drawbacks 176 (38%)
Research would help others, contribute to
scientific advance
250 (32%) Coping with negative results
and possibly other negative information
94 (20%)
Identify cancer risk for family members 141 (18%) Discrimination/privacy/insurance fears 45 (10%)
Provides hope and possible cure 34 (4%) Sceptical of science; possible inconclusive
or false results
36 (8%)
Gives me certainty, control 10 (1%) Responsibility or guilt for genes; fear
of bearing bad news to family
33 (7%)
Exhausting all options, ticked all boxes 10 (1%) Burden of study – travel, surveys, waiting for results 29 (6%)
Testing is easy and non-invasive 2 (0%) Possibility inaccessibility of drug trials if an actionable result was found, or
receiving a placebo drug
28 (6%)
Other 18 (4%)
● May choose more than one
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considered this anxiety to be worth tolerating, with
many noting that all hope would be lost if MTP did not
provide an answer. ‘Well, it’s pretty simple. When you’ve
got no other hope or no other opportunity and no other
idea what the hell is going on, you grab every chance you
can grab.’ (382, male, age 61–70 years)
2) The black box
Participants’ understanding of MTP was generally
poor, despite explanations provided during the consent
process. MTP was viewed as a ‘black box’, the workings
of which were obscure. This was expressed with regard
to three sub-themes: a) Understanding the study, b) The
science, and c) Beyond my capacity.
a) Understanding the study
Participants were generally cognizant of their lack of
understanding, and while some would have liked more
information (and sought it online), this did not affect
their decision to provide consent. The focus of these
participants was on access to new therapy, and they ei-
ther did not care what the access process involved or
were unreservedly accepting of the consent information
provided. Any feelings of frustration tended to focus on
issues of access to the trial. Participants made comments
such as: – ‘Why was I not told of the MoST Program
sooner?’; ‘What would have happened if I had not found
the study online?’ and ‘Why did I have to wait until
treatment options were exhausted before being eligible?’
Specific concerns were held by the majority of partici-
pants who lived in interstate and regional areas, because
access issues related to the costs of travel to the hospital
and city accommodation were troublesome. This frustra-
tion was balanced by another cohort who was overtly
appreciative of their opportunity to join the study and
feeling lucky they had. ‘It’s probably not that important
to actually know … the science behind it. I don’t really
care about (the details) as long as (I get) the treatment
options.’ (340, male, age 41–50 years)
b) Science
The lack of understanding of the testing process
was counter-balanced by a confidence in the ‘power of
science’. This was either expressed as a general trust
in the scientific process, and that any advance would
be advantageous, or personalized by the treating on-
cologists, who were perceived as understanding the
process and able to provide relevant information as
needed. One participant explained: ‘it’s (MTP) more of
a doctor thing. I feel I would like a little bit more in-
formation on it, now that you mention it, it would be
interesting, but, it’s not something I’ve felt the need to
ask about … , but, really, until they know what it is,
tell me if there’s any treatments, and, I’m quite happy
just to leave it in their (the doctor’s) hands.’ (276, fe-
male, age 51–60 years)
c) Beyond my capacity
Many participants acknowledged that they did not
understand the MoST Program and did not attempt to
understand MTP, as they considered genomic testing to
be ‘beyond’ them. While these participants were not
troubled by their ignorance, it was noted that many had
an incorrect understanding of the test implications. This
became evident from wrong inferences, such as being
concerned that having the test may impact their access
to insurance products or confusing somatic with germ-
line results, and thinking that somatic variants would be
passed onto family and could influence reproductive de-
cision-making for their children.
‘I’m weighing up potential benefits (of MTP) for my
children … the down side of that which is … the
potential impact on their lives from the point of view
of life insurance policies, employment and all sorts of
other things.’ (382, male, age 61–70 years)
3) Survival is the priority
Overall, this group of participants were advanced can-
cer sufferers striving to stay alive through access to new
treatment, with subthemes focussing on: a) Preserving
hope; b) Treatment is the priority; and c) Fear the can-
cer, not the treatment.
a) Preserving hope
The MoST Program was perceived as an opportun-
ity to preserve hope for prolonged survival. The par-
ticipants with this view were still ‘trying to fight their
cancer’, eager for ongoing investigation which might
uncover something helpful. They felt that by joining
the MoST Program, they had extra people on their
‘side’, ‘looking out for them’ and helping them. Just be-
ing associated with a big hospital was felt to increase
opportunities for drug trials. ‘ … getting the right
people on side, who are going to help you, and work
with you all the way.’ (323, male, age 61–70 years).
Even if treatment was not available through a study re-
lated to the MoST Program, participants envisioned tak-
ing their results with them to find treatment elsewhere.
Despite being told that the chances of a positive result
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were small, many participants were confident that ‘some-
thing would be found’ to help.
‘One of the reasons I’m doing the (MTP) test is
because it may not be something that may happen
now or one year or five years or 10 years down the
track, but it could.’ (316, male, age 71–80 years).
b) Treatment is the priority
Finding a new treatment was the overriding motiv-
ation for joining the MoST Program for the majority
of these participants. Despite the investigators’ con-
cern regarding the psychological impact of genomic
testing on them, participants were not very interested
in exploring a negative impact for themselves. Non-
cancer information (such as secondary findings) was
viewed as irrelevant and burdensome at a time when
they had ‘more important’ (i.e. existential) things to
consider. Many participants seemed to lack emotional
resources to countenance disclosing germline findings
to family (if these were to be forthcoming), even if
they saw it was important. Generally, they said that
communication of relevant results to relevant bio-
logical relatives would occur if it did not prove to be
too difficult.
c) Fear the cancer, not the treatment
All participants were given the opportunity to discuss
what they saw as the drawbacks to MTP. It was clear
that any fear that existed was a result of progressive dis-
ease, which dominated their thoughts, and not MTP.
The only ‘fear’ associated with testing was the prospect
of a poor survival outcome. Having undergone many
tests previously, genomic testing was seen as just an-
other test, no different to previous tests: ‘Oh, no, that’s
not the testing, that, that impact is just knowing I’m in
stage 4, you know, that, that’s got nothing to do with the
testing, which comes and goes, which comes and goes, it’s
okay.’ (375, female, age 61–70 years).
Discussion
This qualitative study explored the experiences of adults
with advanced cancer 2 weeks after agreeing to undergo
MTP to potentially identify personalised treatment after
all other therapeutic options had been exhausted. This
cohort had a strong desire to find new treatments whilst
being generally unconcerned about the potential to iden-
tify germline variants relevant to family members.
Further, although participants did not clearly understand
the technical details of what genomic testing involved,
participants were happy to trust their oncologist to re-
port relevant information. Some were wary of obtaining
a disappointing outcome, but the majority were quite
hopeful at the time of interview.
All participants appeared to give consent to the study
without reservation, because it was non-invasive, and
represented an opportunity for new therapy. Yet while
MTP is in many ways ‘just another test’, any testing of
the genome carries the possibility that germline variants
may be found which will have implications for both the
participant and their blood relatives. Mandelker and col-
leagues compared tumor and germline sequencing in
1040 patients with advanced cancer and identified clinic-
ally actionable inherited pathogenic variants in the
ACMG notifiable autosomal dominant cancer genes in
9.6% of the sample [7]. Schrader and colleagues found
pathogenic variants in 4.7% of a sample of 1566 patients
with advanced cancer [18]. Despite careful explanation
at the time of consent, there was a wide variability in un-
derstanding of the MTP process and its implications in
our cohort. Previous authors have expressed concern
about the validity of consent in this setting [19]. While
there is an obvious motivation for these patients to
undergo testing, there is some concern that the partici-
pants are not critically reflecting on the fact that being a
MoST participant could provide them with a finding
that has implications for their relatives. As cancer pa-
tients are inundated with information regarding their
disease, including material about treatment and associ-
ated tests, mechanisms of consent to MTP need to facili-
tate patients’ understanding of the test’s potential
germline implications.
A number of qualitative participants expressed
concern about the impact of participation on access to
insurance, a response also found in 10% of the quantita-
tive sample. This finding reflected a misunderstanding
both of the nature of results, but also of the basis of in-
surance policies in Australia. Concern that MTP might
impact access to health insurance was baseless in this
cohort, firstly for participants (as insurance in
Australia is risk-rated only, having advanced cancer
means that this cohort would not be able to access
new risk-rated products anyway) and most family
members (as somatic variants are rarely of germline
origin and findings are relevant for the patient only).
Furthermore, a moratorium on mandatory revelation
of adverse genetic test results for life insurance appli-
cations is imminent in Australia [20]. However, in
other countries, patients experience legitimate anxiety re-
garding genetic discrimination and cost-related barriers to
care [21]. Regardless of local policy, it is of concern if mis-
understanding of the test implications increases patient
distress, or discourages potential beneficiaries from par-
ticipating in MTP protocols [22].
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Some participants noted that possible germline impli-
cations of testing may be a burden for them in the
context of advanced illness. This raises the issue of how
to promote the dissemination of this information – par-
ticularly information that is actionable - to relevant
blood relatives [23–25]. While family members may
elect to not investigate further, it is widely accepted that
they should be given an opportunity to consider this de-
cision for themselves [26–28]. While clinical practice in
this area is still emerging, findings arising from research
like ours may be critical in guiding clinical pathways.
While this cohort had little understanding of genomic
testing, there is scant evidence that patients generally
understand the workings of any medical investigation.
Biesecker and colleagues have commented that so long
as patients understand the ‘gist’ of genetics that may be
sufficient [29]. It also reflects wider ethical consider-
ations of what consent to genomics-based tests should
look like; namely a shift towards more generic consent
that should not assume a granular understanding [30].
What is more important for consent, and which the
current participants themselves desired, was information
on how the test would impact on them personally, as
has been previously reported [31]. The majority of par-
ticipants realised that MTP may be used to access perso-
nalised treatment, and this level of understanding is
commensurate with the level of understanding achieved
when participating in clinical trials and accessing med-
ical interventions. It could be that clinicians and re-
searchers are unduly concerned about patients and
participant’s understanding of the complexity of genomic
testing and its implications, when patients and partici-
pants are able to critically engage with the test process
without having this kind of understanding. This was fur-
ther emphasised by participants who focused their con-
cern on their disease progression rather than on any
investigation, as the desire to live drove and dominated
their decision-making. It has been previously noted that
the perspective of the patient differs from that of a well
person [32]. This point raises the question of genetic ex-
ceptionalism and the degree to which it may influence
or assume a role in decision-making around genomic
testing.
Further, in our study, we found (unrealistic) optimism
and high expectations and hope that an actionable result
and an available drug trial would be available and suc-
cessful, despite being advised of the unlikelihood of this
outcome. There is therefore a potential for emotional
distress given the low likelihood of an effective targeted
treatment. Oncologists may find it difficult to discuss
the negative aspects of prognosis with patients [33],
which can contribute to these unrealistic hopes [34]. Cli-
nicians may need to learn advanced communication
strategies to help patients manage their disappointment
in the case of no actionable results [35]. Well accepted
evidence-based communication strategies, including pa-
tient prompt lists and decision aids, may further facili-
tate communication in this complex setting [36–39].
This study provides useful participant perspectives on
a new form of testing. The strengths of this study is its
ecological validity, as participants were about to undergo
MTP in a clinical context where it may be implemented
in routine care in the near future. Participants were pur-
posively sampled from a large pool, providing a cohort
with diverse demographic and disease characteristics. A
limitation of this study is that participant recall may
have been negatively impacted by the experience of ad-
vanced disease.
Conclusions
This study explored the attitudes of adults with ad-
vanced cancer towards genomic testing for personalized
therapy. We found that management of expectations
may be needed to help patients accept that the chance
of a result that would change cancer treatment is low.
However, in general, participants were both positive and
optimistic about participating in the process of genomic
testing, despite their limited understanding of the test
and its implications. Our ongoing longitudinal follow-up
will elucidate whether this positive view is maintained
following receipt of MTP results.
Additional file
Additional file 1: Interview Schedule. 18 questions which asked of
each interviewee. (DOCX 14 kb)
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